Comment on “Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy”
Journal of the Formosan Medical Association · 2026-05
DOI: 10.1016/j.jfma.2026.05.033 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of the Formosan Medical Association, 2026-05. Verfasst von Madhuri Sathyanarayana. Beteiligte Einrichtung: Department of PG Studies and Research in Biochemistry, Kuvempu University, Karnataka, India. Electronic address: researcherscientific629@gmail.com. Die Arbeit nennt 4 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of PG Studies and Research in Biochemistry, Kuvempu University, Karnataka, India. Electronic address: researcherscientific629@gmail.com.
Zitieren
APA
Sathyanarayana, M. (2026). Comment on “Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy”. Journal of the Formosan Medical Association. https://doi.org/10.1016/j.jfma.2026.05.033
Vancouver
Sathyanarayana M. Comment on “Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy”. Journal of the Formosan Medical Association. 2026. doi:10.1016/j.jfma.2026.05.033
BibTeX
@article{Sathyanarayana2026,
author = {Sathyanarayana, Madhuri},
title = {Comment on “Pyrotinib combined with trastuzumab and chemotherapy in the treatment of HER2-positive metastatic breast cancer after the progression of trastuzumab therapy”},
journal = {Journal of the Formosan Medical Association},
year = {2026},
doi = {10.1016/j.jfma.2026.05.033}
}
EUVIMED